insights_auto
Why is DMN down 2,81%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
0,059 €
arrow_downward
-2,81%(-0,0017) 1D
18 նոյ, 08:04:54 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
138,45 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
138,45 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
ChartMill
·
41 րոպե առաջ
S&P 500 Premarket Movers on Nov. 18
TradingView
·
26 րոպե առաջ
UBS predicts S&P 500 moving up 12% in 2027 but flags major risks around AI
Investopedia
·
1 ժամ առաջ
Stock Market Today: Nasdaq, S&P 500 Futures Rise as Nvidia Shares Jump After Strong Earnings Report; Anthropic IPO on Deck
FOREX.com
·
2 ժամ առաջ
S&P 500 Quietly Shrugs Off the Bitcoin and Silver Selloff
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB